Literature DB >> 26611479

Metastatic pancreatic cancer: abdominal pain in a 22-year-old woman.

Bakul T Roy1, Roshan B Roy2.   

Abstract

Pancreatic cancer remains fourth among cancer-related deaths. Its diagnosis is often missed, owing to its vague abdominal symptoms, leading to a diagnosis of stage IV pancreatic cancer. FOLFIRINOX chemotherapy was administered to the patient in this report, resulting in significant improvement based on tests of biological markers as well as radiographic resolution of the metastatic disease. A keen awareness of this condition along with appropriate diagnostic tests can allow for an earlier diagnosis and may impact its high mortality. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Year:  2015        PMID： 26611479      PMCID： PMC4680250          DOI： 10.1136/bcr-2015-211361

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  6 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  Diagnosis and management of pancreatic cancer.

Authors:  Zaheer S Kanji; Steven Gallinger
Journal:  CMAJ       Date:  2013-04-22       Impact factor: 8.262

Review 4.  Palliative care in pancreatic cancer.

Authors:  Frank J Brescia
Journal:  Cancer Control       Date:  2004 Jan-Feb       Impact factor: 3.302

Review 5.  Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Authors:  Franck Bonnetain; Bert Bonsing; Thierry Conroy; Adelaide Dousseau; Bengt Glimelius; Karin Haustermans; François Lacaine; Jean Luc Van Laethem; Thomas Aparicio; Daniela Aust; Claudio Bassi; Virginie Berger; Emmanuel Chamorey; Benoist Chibaudel; Laeticia Dahan; Aimery De Gramont; Jean Robert Delpero; Christos Dervenis; Michel Ducreux; Jocelyn Gal; Erich Gerber; Paula Ghaneh; Pascal Hammel; Alain Hendlisz; Valérie Jooste; Roberto Labianca; Aurelien Latouche; Manfred Lutz; Teresa Macarulla; David Malka; Muriel Mauer; Emmanuel Mitry; John Neoptolemos; Patrick Pessaux; Alain Sauvanet; Josep Tabernero; Julien Taieb; Geertjan van Tienhoven; Sophie Gourgou-Bourgade; Carine Bellera; Simone Mathoulin-Pélissier; Laurence Collette
Journal:  Eur J Cancer       Date:  2014-09-22       Impact factor: 9.162

6.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.

Authors:  Sonia A Melo; Linda B Luecke; Christoph Kahlert; Agustin F Fernandez; Seth T Gammon; Judith Kaye; Valerie S LeBleu; Elizabeth A Mittendorf; Juergen Weitz; Nuh Rahbari; Christoph Reissfelder; Christian Pilarsky; Mario F Fraga; David Piwnica-Worms; Raghu Kalluri
Journal:  Nature       Date:  2015-06-24       Impact factor: 69.504
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.